172 related articles for article (PubMed ID: 36690683)
1. Botanical inhibitors of SARS-CoV-2 viral entry: a phylogenetic perspective.
Risener CJ; Woo S; Samarakoon T; Caputo M; Edwards E; Klepzig K; Applequist W; Zandi K; Goh SL; Downs-Bowen JA; Schinazi RF; Quave CL
Sci Rep; 2023 Jan; 13(1):1244. PubMed ID: 36690683
[TBL] [Abstract][Full Text] [Related]
2. Screening of Natural Products Inhibitors of SARS-CoV-2 Entry.
González-Maldonado P; Alvarenga N; Burgos-Edwards A; Flores-Giubi ME; Barúa JE; Romero-Rodríguez MC; Soto-Rifo R; Valiente-Echeverría F; Langjahr P; Cantero-González G; Sotelo PH
Molecules; 2022 Mar; 27(5):. PubMed ID: 35268843
[TBL] [Abstract][Full Text] [Related]
3. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
Joseph J; Karthika T; Das VRA; Raj VS
Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
[TBL] [Abstract][Full Text] [Related]
4. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
5. Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2.
Liu Y; Hu G; Wang Y; Ren W; Zhao X; Ji F; Zhu Y; Feng F; Gong M; Ju X; Zhu Y; Cai X; Lan J; Guo J; Xie M; Dong L; Zhu Z; Na J; Wu J; Lan X; Xie Y; Wang X; Yuan Z; Zhang R; Ding Q
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33658332
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration.
Yang Q; Hughes TA; Kelkar A; Yu X; Cheng K; Park S; Huang WC; Lovell JF; Neelamegham S
Elife; 2020 Oct; 9():. PubMed ID: 33103998
[TBL] [Abstract][Full Text] [Related]
7. The Natural Stilbenoid (-)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants.
Tietjen I; Cassel J; Register ET; Zhou XY; Messick TE; Keeney F; Lu LD; Beattie KD; Rali T; Tebas P; Ertl HCJ; Salvino JM; Davis RA; Montaner LJ
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0077221. PubMed ID: 34543092
[TBL] [Abstract][Full Text] [Related]
8. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
9. Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants.
Nair MS; Huang Y; Fidock DA; Polyak SJ; Wagoner J; Towler MJ; Weathers PJ
J Ethnopharmacol; 2021 Jun; 274():114016. PubMed ID: 33716085
[TBL] [Abstract][Full Text] [Related]
10. Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19.
Cao J; Liu Y; Zhou M; Dong S; Hou Y; Jia X; Lan X; Zhang Y; Guo J; Xiao G; Wang W
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215943
[TBL] [Abstract][Full Text] [Related]
11. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.
Xu M; Pradhan M; Gorshkov K; Petersen JD; Shen M; Guo H; Zhu W; Klumpp-Thomas C; Michael S; Itkin M; Itkin Z; Straus MR; Zimmerberg J; Zheng W; Whittaker GR; Chen CZ
SLAS Discov; 2022 Mar; 27(2):86-94. PubMed ID: 35086793
[TBL] [Abstract][Full Text] [Related]
12. Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry.
Ao Z; Chan M; Ouyang MJ; Olukitibi TA; Mahmoudi M; Kobasa D; Yao X
PLoS One; 2021; 16(6):e0251649. PubMed ID: 34106944
[TBL] [Abstract][Full Text] [Related]
13. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2.
Rowland R; Brandariz-Nuñez A
Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876
[TBL] [Abstract][Full Text] [Related]
16. Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor Interaction.
Kim YS; Kwon EB; Kim B; Chung HS; Choi G; Kim YH; Choi JG
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293371
[TBL] [Abstract][Full Text] [Related]
17.
Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
[TBL] [Abstract][Full Text] [Related]
18. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
19. Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels.
Zeng Q; Antia A; Casorla-Perez LA; Puray-Chavez M; Kutluay SB; Ciorba MA; Ding S
mBio; 2024 Mar; 15(3):e0228723. PubMed ID: 38349185
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Cytotoxic and Antiviral Effects of Small Molecules Selected by In Silico Studies as Inhibitors of SARS-CoV-2 Cell Entry.
Carvalhal F; Magalhães AC; Rebelo R; Palmeira A; Resende DISP; Durães F; Maia M; Xavier CPR; Pereira L; Sousa E; Correia-da-Silva M; Vasconcelos MH
Molecules; 2023 Oct; 28(20):. PubMed ID: 37894682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
